Vaccinex PE Ratio 2017-2021 | VCNX

Current and historical p/e ratio for Vaccinex (VCNX) from 2017 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Vaccinex PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Vaccinex PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 1.83 0.00
2021-06-30 2.80 $-0.91 0.00
2021-03-31 2.98 $-1.09 0.00
2020-12-31 2.07 $-1.28 0.00
2020-09-30 1.78 $-1.66 0.00
2020-06-30 3.61 $-1.78 0.00
2020-03-31 4.00 $-2.16 0.00
2019-12-31 4.85 $-2.50 0.00
2019-09-30 7.17 $-2.12 0.00
2019-06-30 5.52 $-2.49 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.056B $0.001B
Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76